Last reviewed · How we verify
Furosemide and Hydrochlorothiazide Followed by Furosemide
Furosemide and Hydrochlorothiazide Followed by Furosemide, marketed by Shiraz University of Medical Sciences, is a combination therapy currently available in the market. The key composition patent is set to expire in 2028, providing a period of exclusivity and potential revenue protection. The primary risk is the lack of reported key trial results and revenue data, which may limit investor confidence and market adoption.
At a glance
| Generic name | Furosemide and Hydrochlorothiazide Followed by Furosemide |
|---|---|
| Also known as | Lasix and Microzide Followed by Lasix |
| Sponsor | Shiraz University of Medical Sciences |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure (PHASE2, PHASE3)
- Influence of Lung Ultrasonography on the Prognosis and Postoperative Outcomes in Cardiac Surgical Patients (NA)
- Phototoxicity of Frequently Prescribed Medicines (NA)
- Nephropathy In Type 2 Diabetes and Cardio-renal Events (PHASE4)
- Role of Acetazolamide and Hydrochlorothiazide Followed by Furosemide in Treating Nephrotic Edema (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: